Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel H Greig

Showing results (311-320 of 332) with videos related to

Pageof 34
Sort By:
Journal of Neurotrauma|March 15, 2016
Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in RatsYu-Wen Yu, Tsung-Hsun Hsieh, Kai-Yun Chen, et al.
Experimental Neurology|May 7, 2016
Corrigendum to "Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity", [Exp. Neurol. 273 (2015), 151-160]Erez Eitan, Emmette R Hutchison, Nigel H Greig, et al.
Experimental Neurology|August 17, 2015
Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunityErez Eitan, Emmette R Hutchison, Nigel H Greig, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 9, 2022
Microglia Drive Pockets of Neuroinflammation in Middle AgeEric N Moca, Daniela Lecca, Keenan T Hope, et al.
CNS & Neurological Disorders Drug Targets|September 18, 2014
Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitusGhulam M Ashraf, Nigel H Greig, Taqi A Khan, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2009
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and ParkinsonismYazhou Li, TracyAnn Perry, Mark S Kindy, et al.
Lancet (London, England)|August 8, 2017
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trialDilan Athauda, Kate Maclagan, Simon S Skene, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
A new therapeutic approach for Parkinson's disease: dual targeting of α-Synuclein aggregation and microglial function by the novel immunomodulator 3-MonothiopomalidomideMaria Francesca Palmas, Khosro Aminzadeh, Matteo Runfola, et al.
Cell Transplantation|May 17, 2019
Pomalidomide Reduces Ischemic Brain Injury in RodentsYan-Rou Tsai, David Tweedie, Ignacio Navas-Enamorado, et al.
ACS Pharmacology & Translational Science|April 16, 2021
Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's DiseaseVicki Wang, Tung-Tai Kuo, Eagle Yi-Kung Huang, et al.
Pageof 34

Showing results (311-320 of 332) with videos related to

Sort By:
Pageof 34
Journal of Neurotrauma|March 15, 2016
Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in RatsYu-Wen Yu, Tsung-Hsun Hsieh, Kai-Yun Chen, et al.
Experimental Neurology|May 7, 2016
Corrigendum to "Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity", [Exp. Neurol. 273 (2015), 151-160]Erez Eitan, Emmette R Hutchison, Nigel H Greig, et al.
Experimental Neurology|August 17, 2015
Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunityErez Eitan, Emmette R Hutchison, Nigel H Greig, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 9, 2022
Microglia Drive Pockets of Neuroinflammation in Middle AgeEric N Moca, Daniela Lecca, Keenan T Hope, et al.
CNS & Neurological Disorders Drug Targets|September 18, 2014
Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitusGhulam M Ashraf, Nigel H Greig, Taqi A Khan, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2009
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and ParkinsonismYazhou Li, TracyAnn Perry, Mark S Kindy, et al.
Lancet (London, England)|August 8, 2017
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trialDilan Athauda, Kate Maclagan, Simon S Skene, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
A new therapeutic approach for Parkinson's disease: dual targeting of α-Synuclein aggregation and microglial function by the novel immunomodulator 3-MonothiopomalidomideMaria Francesca Palmas, Khosro Aminzadeh, Matteo Runfola, et al.
Cell Transplantation|May 17, 2019
Pomalidomide Reduces Ischemic Brain Injury in RodentsYan-Rou Tsai, David Tweedie, Ignacio Navas-Enamorado, et al.
ACS Pharmacology & Translational Science|April 16, 2021
Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's DiseaseVicki Wang, Tung-Tai Kuo, Eagle Yi-Kung Huang, et al.
Pageof 34